Keyword: EuroBiotech Report
In this week's EuroBiotech Report, GSK plans R&D cuts, Genfit gets breakthrough status and Kiadis pens deal to buy CytoSen.
In our EuroBiotech roundup this week, Hookipa prices IPO, Affimed eyes end of clinical hold and Cassiopea posts hair loss data.
The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.
GSK is set to lay off a small number of R&D employees at its Stevenage, U.K., site as part of a wider rethink of its drug development operation.
The all-stock deal will give Kiadis control of a preclinical natural killer cell therapy and see it add CAR-T pioneer Carl June to its scientific advisory board.
In this week's EuroBiotech Report, Bayer moves into Kendall Square, Poxel's shares jump, Kymab grabs former German Merck executive and more.
In this week's EuroBiotech Report, CIC committed nearly $200 million to biotechs, AgomAb raised funds, Novartis penned a biobucks pact and more.
The financing will support existing portfolio companies such as Bicycle and Carrick Therapeutics and equip CIC to back additional businesses.
The phase 1 trial linked the drug to a 45% response rate in a subpopulation of solid tumor patients resistant or intolerant to a prior TRK inhibitor.
In this week's EuroBiotech Report, U.K. VC funding jumps 35%, Ono joins U.K. immuno-oncology alliance and Sofinnova, NEA back Swiss startup.